HZNP
NASDAQHorizon Therapeutics Public Limited Company
Latest news
25 items- PRDeep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual MeetingIssues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom Highlights Concerns that Company's Misguided Acquisition Strategy Will Destroy Value and Prevent Dynavax from Maximizing the Benefit of Heplisav for Shareholders and Patients In Deep Track's View, Focusing on Heplisav Could Result in Nearly $2 Billion of Cash Being Returned to Shareholders by the End of 2030 Details Board's Poor Governance, Reactive Entrenchment Maneuvers, and Unwillingness to Work Constructively Believes Its Slate of Director Nominees Would Collectively Bring Valuable Shareholder Perspective and Independence as Well
- SECSEC Form 15-12G filed by Horizon Therapeutics Public Limited Company15-12G - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
- INSIDERWatkins Thomas returned $20,550,600 worth of Ordinary Shares to the company (176,400 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERMahony Susan returned $2,172,842 worth of Ordinary Shares to the company (18,651 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERWitz Pascale returned $5,353,292 worth of Ordinary Shares to the company (45,951 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERGrey Michael G returned $11,346,168 worth of Ordinary Shares to the company (97,392 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERDaniel William F returned $9,271,652 worth of Ordinary Shares to the company (79,585 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERHimawan Jeff returned $10,371,762 worth of Ordinary Shares to the company (89,028 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERShannon James Samuel returned $6,616,501 worth of Ordinary Shares to the company (56,794 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERSantini Gino returned $13,935,031 worth of Ordinary Shares to the company (119,614 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERMcilvenny Patrick returned $800,821 worth of Ordinary Shares to the company (6,874 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERPasternak Andy returned $6,563,377 worth of Ordinary Shares to the company (56,338 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERThompson Elizabeth H.Z. returned $1,697,988 worth of Ordinary Shares to the company (14,575 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERCox Aaron returned $64,774 worth of Ordinary Shares to the company (556 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERWalbert Timothy P returned $101,907,909 worth of Ordinary Shares to the company (874,746 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERDesjardin Michael A. returned $14,776,627 worth of Ordinary Shares to the company (126,838 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERClayton Sean M. returned $978,600 worth of Ordinary Shares to the company (8,400 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- INSIDERSherman Jeffrey W returned $27,349,424 worth of Ordinary Shares to the company (234,759 units at $116.50), closing all direct ownership in the company (SEC Form 4)4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)
- SECSEC Form S-8 POS filed by Horizon Therapeutics Public Limited CompanyS-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
- SECSEC Form S-8 POS filed by Horizon Therapeutics Public Limited CompanyS-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
- SECSEC Form S-8 POS filed by Horizon Therapeutics Public Limited CompanyS-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
- SECSEC Form S-8 POS filed by Horizon Therapeutics Public Limited CompanyS-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
- SECSEC Form S-8 POS filed by Horizon Therapeutics Public Limited CompanyS-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
- SECSEC Form S-8 POS filed by Horizon Therapeutics Public Limited CompanyS-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
- SECSEC Form S-8 POS filed by Horizon Therapeutics Public Limited CompanyS-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
HZNP FAQ
7 questionsWhat does Horizon Therapeutics Public Limited Company do?
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI...Where does HZNP stock trade?
Horizon Therapeutics Public Limited Company (HZNP) is listed on NASDAQ.What sector and industry is HZNP in?
Horizon Therapeutics Public Limited Company operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Horizon Therapeutics Public Limited Company go public?
Horizon Therapeutics Public Limited Company (HZNP) completed its IPO in 2011.What are analysts saying about HZNP?
Horizon Therapeutics Public Limited Company has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2022-11-01.What companies are similar to HZNP?
Notable peers in the same industry include JAZZ (Jazz Pharmaceuticals plc), ISEE (IVERIC bio Inc.), HZN (Horizon Global Corporation). Compare HZNP side-by-side with any of them on Quantisnow.How can I track HZNP on Quantisnow?
Quantisnow aggregates Horizon Therapeutics Public Limited Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HZNP to receive live email and push alerts on every new disclosure.